Use of Gene-Expression Profiling to Identify Prognostic Subclasses in Adult Acute Myeloid Leukemia

New England Journal of Medicine

Volumn 350, Issue 16, 2004, Pages 1605-1616

  Bullinger, Lars ^a   Döhner, Konstanze ^c   Bair, Eric ^b   Fröhling, Stefan ^c   Schlenk, Richard F ^c   Tibshirani, Robert ^b   Döhner, Hartmut ^c   Pollack, Jonathan R ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADULT DISEASE; ALGORITHM; ARTICLE; BLOOD SAMPLING; BONE MARROW; CANCER CLASSIFICATION; CANCER SURVIVAL; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN CELL; KARYOTYPING; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; VALIDATION PROCESS;

ACUTE DISEASE; ADULT; ALGORITHMS; CHROMOSOME ABERRATIONS; CLUSTER ANALYSIS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID; MULTIVARIATE ANALYSIS; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 16544369516     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa031046     Document Type: Article

References (45)

1. Giles FJ, Keating A, Goldstone AH, Avivi I, Willman CL, Kantajian HM. Acute myeloid leukemia. Hematology (Am Soc Hematol Educ Program) 2002:73-110.
2. Lowenberg B. Prognostic factors in acute myeloid leukaemia. Best Pract Res Clin Haematol 2001;14:65-75.
3. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998;92:2322-33.
4. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Pes 1998;58:4173-9.
5. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-36.
6. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075-83.
7. Mrozek K, Heinonen K, Bloomfield CD. Clinical importance of cytogenetics in acute myeloid leukaemia. Best Pract Res Clin Haematol 2001;14:19-47.
8. Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002;100:4372-80.
9. Kottaridis PD, Gale PE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001;98:1752-9.
10. Caligiuri MA, Strout MP, Lawrence D, et al. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res 1998;58:55-9.
11. Dohner K, Tobis K, Ulrich R., et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 2002;20:3254-61.
12. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100;1532-42.
13. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
14. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-47.
15. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74.
16. Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002;30:41-7.
17. Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002;1:133-43.
18. Frohling S, Skelin S, Liebisch C, et al. Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. J Clin Oncol 2002;20:2480-5.
19. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-8.
20. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
21. Gollub J, Ball CA, Binkley G, et al. The Stanford Microarray Database: data access and quality assessment tools. Nucleic Acids Res 2003;31:94-6.
22. Nielsen TO, West RB, Linn SC, et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 2002;359:1301-7.
23. Raychaudhuri S, Stuart JM, Altman RB. Principal components analysis to summarize microarray experiments: application to sporulation time series. Pac Symp Bicomput 2000;5:455-66.
24. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21. [Erratum, Proc Natl Acad Sci U S A 2001;98:10515.]
25. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21. [Erratum, Proc Natl Acad Sci U S A 2001;98:10515.]
26. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 2002;99:6567-72.
27. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49-54.
28. Virtaneva K, Wright FA, Tanner SM, et al. Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. Proc Natl Acad Sci U S A 2001;98:1124-9.
29. Tanabe S, Zeleznik-Le NJ, Kobayashi H, et al. Analysis of the t(6;11)(q27;q23) in leukemia shows a consistent breakpoint in AF6 in three patients and in the ML-2 cell line. Genes Chromosomes Cancer 1996;15:206-16.
30. Galmarini CM, Thomas X, Calvo F, et al. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol 2002;117:860-8.
31. Kumano K, Chiba S, Shimizu K, et al. Notchl inhibits differentiation of hematopoietic cells by sustaining GATA-2 expression. Blood 2001;98:3283-9.
32. Mizuno S-I, Chijiwa T, Okamura T, et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 2001;97:1172-9.
33. Gerber HP, Malik AK, Solar GP, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002;417:954-8.
34. Schuch G, Machluf M, Bartsch G Jr, et al. In vivo administration of vascular endothelial growth Factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. Blood 2002;100:4622-8.
35. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
36. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002;415:436-42.
37. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
38. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-24.
39. Burgering BM, Kops GJ. Cell cycle and death control: long Eve Forkheads. Trends Biochem Sci 2002;27:352-60.
40. So CW, Cleary ML. Common mechanism for oncogenic activation of MLL by forkhead family proteins. Blood 2003;101:633-9.
41. van Oostveen J, Bijl J, Raaphorst F, Walboomers J, Meijer C. The role of homeobox genes in normal hematopoiesis and hematological malignancies. Leukemia 1999;13:1675-90.
42. Thorsteinsdottir U, Sauvageau G, Hough MR, et al. Overexpression of HOXA10 in murine hematopoietic cells perturbs both myeloid and lymphoid differentiation and leads to acute myeloid leukemia. Mol Cell Biol 1997;17:495-505.
43. Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Pev Genomics Hum Genet 2002;3:179-98.
44. Schoch C, Kohlmann A, Schnittger S, et al. Acute myeloid leukemias with reciprocal rearrangements can be distinguished by spepific gene expression profiles. Proc Natl Acad Sci U S A 2002;99:10008-13.
45. Kroon E, Krosl J, Thorsteinsdottir U, Baban S, Buchberg AM, Sauvageau G. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meisla but not Pbx1b. EMBO J 1998;17:3714-25.